Last reviewed · How we verify

NCT06305130

Prognostic Value of Performance Scores in Patients Undergoing Surgery for Upper Tract Urothelial Carcinoma

Completed Last updated 12 March 2024
What this trial tests

trial testing No intervention in Carcinoma, Transitional Cell (RENI) in 2,515 participants. Completed in 31 December 2023.

Timeline
1 January 1988
Primary endpoint
31 December 2023
31 December 2023

Quick facts

Lead sponsorKaohsiung Medical University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment2,515
Start date1 January 1988
Primary completion31 December 2023
Estimated completion31 December 2023

Drugs / interventions tested

Conditions studied

Sponsor

Kaohsiung Medical University

Who can join

Eligibility, any sex, with Carcinoma, Transitional Cell (RENI). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim: to comprehensively evaluate the prognostic value of preoperative ECOG-PS scores and ASA scores in patients undergoing radical nephroureterectomy (RNU) for upper tract urothelial carcinoma. Methods: multicentered cohort study

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Preoperative ECOG performance status as a predictor of outcomes in upper tract urothelial cancer surgery.
    Yang TM, Chen IA, Yu CC, Yang CR, et al · · 2025 · cited 2× · PMID 40133366 · DOI 10.1038/s41598-025-95128-1

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other Kaohsiung Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06305130.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing